Johnson & Johnson (JNJ) reported an earnings beat for its 4th quarter, ending 12/31/2022. Earnings per share got here in at $2.35, versus the anticipated $2.24.
The reported income of $23.71 billion represents a lower of -0.44% in comparison with the earlier quarter, and a lower of -4.46% in comparison with the identical interval final yr.
For the 1st quarter, analysts venture earnings of $2.56 per share.
Usually, earnings bulletins have an effect on a inventory’s value. See a historical past of earnings-related value modifications for JNJ inventory.
What’s Subsequent for Johnson & Johnson, Put up-Earnings?
In accordance with TipRanks, the common analyst consensus on JNJ inventory is a Average Purchase. This consensus is predicated on 6 analyst scores made prior to now 3 months. Johnson & Johnson’s common value goal of $189.50 implies upside potential of 12.59% from present ranges.
See our Earnings Calendar for a full listing of this week’s earnings releases.
Backside Line
An earnings beat can signify constructive motion forward for a inventory’s value. At the moment, JNJ value is $168.31, indicating a 5-day drop of -0.72%.
About Johnson & Johnson
Johnson & Johnson offers healthcare merchandise throughout three segments: Shopper, Pharmaceutical, and Medical Gadgets. The Shopper phase contains merchandise used within the child care, oral care, magnificence, over-the-counter pharmaceutical, ladies’s well being, and wound care markets. The Pharmaceutical phase focuses on therapeutic areas resembling immunology, infectious ailments advert vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Gadgets phase provides merchandise used within the orthopedic, surgical procedure, cardiovascular, diabetes care, and eye well being fields. The corporate was based by Robert Wooden Johnson I, James Wooden Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ..
Study extra about JNJ financials right here
